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Abstract 
Hereditary nonpolyposis colorectal cancer (HNPCC) is associated with germline 
alternations in several mismatch repair (MMR) genes. Mutations in hMLH1 account for the 
majority of HNPCC cases with about one third of them being missense mutations. As such, a 
particular missense mutation (C.1165 c>t R389W hMLH1) has been found in one Danish family 
suspected with HNPCC. Due to that the focus of this investigation is to evaluate the pathogenicity 
of this mutation. This would be done by pursuing clinical and biochemical approaches. First the 
medical history of the HNPCC suspected family is being analyzed in relation to Amsterdam criteria 
I and II. Consequently, it is being suggested that the family is HNPCC-related based on the 
Amsterad criteria II. Moreover, a microscopic analysis of subcellular localization of the fluorescent 
hMLH1 protein with the C.1165 c>t R389W mutation has been done. The results of the 
investigation indicate that the C.1165 c>t R389W hMLH1 protein might be translocated into the 
nucleus of the cells, similarly to the wild type protein. This result is also theoretically correlated 
with the fact that R389W is sited within the linker domain of hMLH1.  
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1. Introduction 
The DNA mismatch repair (MMR) system is a biological pathway that is essential for 
maintenance of genomic stability and reduction of mutation load of DNA. The primary specificity 
of MMR is recognition and removal of the base-base mismatches along with the insertion-deletion 
mispairs generated during DNA replication and recombination, two fundamental cellular processes. 
By reducing the number of replication-associated errors, MMR prevents mutations from becoming 
permanent in the dividing cells [Li, 2008]. 
The MMR is also involved in some other cellular processes, such as cell cycle arrest and 
induced cell death in response to some types of the DNA damage [Li, 2008]. 
There are several proteins involved in different steps of the mismatch repair process that 
function as either homodimers (in prokaryotes), or as heterodimer complexes (in eukaryotes). 
Mutations in some of the human genes encoding for these proteins are reported to be the cause of an 
inherited autosomal dominant disorder HNPCC (Hereditary Nonpolyposis Colorectal Cancer). The 
germ-line mutations in human DNA mismatch repair genes of hMLH1 and hMSH2 account for 
about 90 per cent of all mutations identified in MMR genes [Park, et al., 2006]. 
Particularly, a cytosine to thymine missence mutation at nucleotide position 1165 causing 
arginine (R) to tryptophan (W) change at codon 389 in hMLH1 has been reported in one member of 
an HNPCC related family. This particular mutation (abbreviated as C.1165 c>t R389W-hMLH1) is 
the focus of our project. The problem formulation of this investigation is the following: 
Examination and evaluation of pathogenicity of C.1165 c>t R389W hMLH1 mutation based on 
hMLH1/hPMS2 nuclear localization in vivo. 
By investigating the pathogenicity of C.1165 c>t R389W hMLH1 we would be able to find 
out whether this mutation is disease causing in the HNPCC related families. If the nature of C.1165 
c>t R389W hMLH1 mutation is pathogenic, then individuals suspected with HNPCC can be 
screened for this particular mutation in order to determine whether they need to go through the 
surveillance program. 
With the intention of investigating the problem, several functional assays of the C.1165 c>t 
R389W hMLH1 protein can be carried out. We have chosen to apply only one particular functional 
assay. In this assay a vector carrying the C.1165 c>t R389W hMLH1 gene would be created 
experimentally and expressed in human MMR-deficient and MMR–proficient cells along with the 
empty vector (pEYFP) and the wild type vector (pEYFP-hMLH1). Then a conclusion would be 
drawn based on comparison of the nuclear localization of hMLH1/hPMS2 of the three vector types.  
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However, in order to do that we need to understand the principles of the mismatch repair 
mechanisms, the nuclear translocation of the MMR proteins and the distribution of the hMLH1 
mutations associated with HNPCC. Moreover, we need to know the assessment criteria of HNPCC 
diagnostics. All of these theories would be introduced in later chapters of this report.  
 
2. Mismatch repair system 
Here the mismatch repair mechanisms are considered first in prokaryotic cells and then in 
eukaryotic cells. After that the Hereditary Nonpolyposis Colon Cancer is introduced as a disease 
caused by some of the MMR genes deficiencies.  
2.1 MMR in prokaryotic cells 
Proteins involved in the mismatch repair system (Mut proteins) were originally recognized 
in prokaryotic cells. The mismatch repair system of a prototypical Escheria coli (E. coli) has been 
extensively characterized from genetical and biochemical points of view. MMR is a biological 
pathway highly conserved throughout evolution. Therefore, studying prokaryotic E. coli MMR 
provides an excellent model for MMR in eukaryotic cells. The focus in this section is to explain the 
E. coli MMR briefly in order to provide a better understanding of the MMR in eukaryotic cells.  
The early investigations of the E. coli MMR have shown that the mismatch repair is strand 
specific to the newly synthesized DNA strand and can proceed in either 5´-3´or 3´-5´directions. The 
three major protein components involved in the E. coli mismatch repair are MutS and MutL ATP-
ases and MutH methylation-sensitive endonuclease. It has been shown that loss of these proteins 
intensifies the accumulation of DNA replication errors resulting in a “mutator phenotype” [Harfe, et 
al., 2000].  
The function of MutS is to recognize DNA base-mismatches and small nucleotide 
insertion/deletion mispairs of up to 4 nucleotides in length [Harfe, et al., 2000]. MutS protein is a 
homodimer, however acts as a structural heterodimer [Harfe, et al., 2000; Li, 2008]. This is 
explained by the fact that the monomer units of MutS are sequentially identical, but different in 
structure and function [Li, 2008]. It has been shown that the C-terminal end of the MutS protein is 
involved in the dimerization, while the N-terminal end binds to a mismatch containing DNA. Both 
monomers come in contact with the DNA mismatch forming a clamp [Harfe, et al., 2000]. 
The E. coli DNA is methylated at the N6 position of adenine in dGATC sequence. 
Throughout the replication the newly synthesized strand is temporarily unmethylated. Consequently, 
it is the presence of the hemimethylated dGATC sequence that determines the discrimination of the 
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nascent (newly synthesized) strand.  The function of the MutH protein in this mechanism is to bind 
to hemimethylated dGATC sites and to incise the nascent strand. Then the mismatch excision is 
started at this strand specific nick [Li, 2008].  
MutL is a multifunctional protein mainly important for coupling the mismatch recognition 
with the MMR downstream cascades. Firstly the MutL couples with the MutS, forming a protein 
complex. Secondly, by enhancing the ATP-hydrolysis MutL is able to activate the MutH and to 
stimulate its endonuclease activity. Next, MutL loads MutU (Helicase II/UvrD) at the site of MutH-
induced nick. In this way it facilitates DNA unwinding and separation of the nascent strand 
[Byermyer, et al., 1999]. Recent studies have shown that MutL may promote binding of DNA 
polymerase III to the intermediates of MMR, suggesting that MutL is also involved in DNA 
replication [Li, 2008].  
                
                
               
            
          
             
 
      
     Figure 1: MMR in prokaryotic cells. 
     The mismatch repair mechanisms in 
prokaryotic cells occurring after the DNA 
replication are presented on the figure. A 
black point on the figure signifies the 
mismatch site. All other participants in 
prokaryotic MMR mechanisms are 
specified.  
     First the MutS homodimer binds to the 
mismatch site, while the MutH binds to the 
hemimethylated site. Then the MutL 
couples with MutS in a protein complex, 
forming a loop surrounding the mismatch. 
MutH is becoming activated by the MutL 
via ATP hydrolysis and makes a nick on 
unmethylated strand containing the DNA 
mismatch.  
     Then depending on the distance between 
strand nick and mismatch site, either the 5’-
3’ exonucleases (EvoVII or RecJ) or the 3’-
5’ exonucleases (ExoI or ExoX) are 
required to remove the mismatch DNA. 
SSB participates in the DNA removal 
protecting the single stranded template 
DNA.  
     PolIII and DNA ligase are involved in 
the repair mechanisms of the mismatch 
strand. At last the new strand is methylated 
by DAM. 
     Figure reproduced from Lützen, (2005). 
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Next, depending on the distance between the strand nick and the mismatch site, either one of 
the 5´-3´exonucleases (EvoVII or RecJ), or one of the 3´-5´exonucleases (ExoI or ExoX) excise the 
strand nick and create a gap. The last step of the E. coli MMR procedure is DNA resynthesis and 
ligation, carried out by DNA polymerase holoenzyme III (pol III), single strand breaks (SSB) and 
DNA ligase [Li, 2008]. At last, the E.coli DNA is fully methylated by DNA adenine 
methyltransferase (DAM) [Lützen, 2005]. All of the E.coli MMR mechanisms described in this 
section are presented in figure 1. 
2.2 MMR in eukaryotic cells 
There are some strong similarities between E. coli MMR and human MMR systems, 
particularly substrate specificity, bi-directionality, and nick-directed strand specificity [Li, 2008]. 
The initial steps of MMR in prokaryotic and eukaryotic cells are very similar: MutS homologs 
recognize and bind to mismatches and ATP and then engage MutL homologs [Schofield, et al., 
2003]. Yet, unlike E. coli, all eukaryotic organisms analyzed to date possess multiple heterodimer 
complexes of MutS and MutL homologs, each composed of two MSH and MLH proteins 
respectively [Harfe, et al., 2000]. The mismatch repair in human proceeds in three basic steps as 
described below. 
2.2.1 Recognition of DNA lesions 
The DNA mismatches are recognized by two MutS complexes. All in all six different MutS 
homologs (MSH1 to 6) have been identified in eukaryotic cells and designated in accordance with 
the designations given to the yeast proteins. However, as sighted by Buermyer, et al. (1999) the 
MSH1 homolog has not been reported in mammals to date. Moreover, MSH4 and MSH5 have 
shown to function in meiotic recombination and not in mutation avoidance [Buermyer, et al., 1999]. 
Therefore, mammals possess only three MutS homologs that are involved in the mismatch repair 
process, namely MSH2, MSH3 and MSH6.  
MSH2 binds with either MSH6 or MSH3, forming either the MutSα or MutSβ complexes 
respectively. The former heterodimer accounts for 80-90% of the cellular MSH2 [Modrich, 2006]. 
Both MutSα and MutSβ are ATPases playing an essential role in mismatch recognition and repair 
initiation. However, the heterodimer complexes have different substrate specifities and thus, MutSα 
and MutSβ carry out different functions in MMR. While MutSα recognizes both the base-
mismatches and insertion/deletion (ID) mismatches of 1 or 2 nucleotides, MutSβ is only able to 
recognize larger ID mismatches [Li, 2008; Modrich, 2006]. 
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2.2.2 Strand discrimination 
After a newly synthesized strand containing the incorrect DNA information is recognized, it 
must be selectively removed and re-synthesized. In case when this does not happen the replication 
error is equally likely to be used either as a template for repair, or to be repaired [Harfe, et al., 2000]. 
Therefore, strand discrimination is an essential step in MMR of all organisms. The strand 
discrimination signal is defined as a strand specific nick in both prokaryotic and eukaryotic cells. 
Yet, the nicking activity in eukaryotic cells is not fully understood. 
 As reported by Christmann, et al. (2003), the newly synthesized strand may be identified by 
non-ligated single strand breaks (SSB) arising as a result of replication. However, a great distance 
can separate the SSB and the mismatch. In this case it becomes unclear how the MutSα is able to 
recognize them. An answer to this uncertainty may be explained by the role of ATP in the MMR 
process. 
 There are two models describing the ATP/ADP binding of MSH2 and MSH6 proteins and 
ATP hydrolysis. In the molecular switch model MutSα-ADP complex is assumed to be in an 
“active state” that recognizes and binds the mismatch. This causes the ADP to ATP transition and 
stimulates the intrinsic ATPase activity, resulting in conformational changes and in the formation of 
hydrolysis-independent sliding clamp. The clamp diffuses from the mismatch passively and signals 
the MMR proteins to dissociate from the “inactive state” of DNA. In this model the ATP hydrolysis 
by MutSα triggers the conformational changes enabling the binding of MutLα, while the ATP 
binding signals the downstream events of the formation of ternary complex with MutLα and sliding 
from the mismatch to the strand break [Christmann, et al., 2003]. 
In contrast, in the hydrolysis-driven translocation model the MutSα heterodimer uses the 
energy from ATP hydrolysis to move actively along the DNA strand from the site of mismatch 
recognition to a site responsible for signalling the strand specificity, likely the SSB. Formation of a 
complex composed of MutSα and MutLα happens at this signalling site [Christmann, et al., 2003]. 
In this model ATP reduces the mismatch-binding affinity of the MutSα heterodimer, while the ATP 
hydrolysis drives one-directional translocation of MutS proteins along the DNA strand until the 
discrimination signal is sent, then forming a DNA loop [Li, 2008]. 
The two models described above are generally classified into the “cis-” or “moving” models. 
Another “trans-” or “stationary” model suggests that interactions within the MMR proteins induce 
DNA bending or looping bringing the two distant sites together. In such a way the MutSα 
heterodimers remain stationary at the mismatches sites, while the MutS ATPase activity verifies the 
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mismatch binding and authorises the downstream deletion [Li, 2008]. All of these three models are 
presented in figure 3 below (section 2.2.3).    
2.2.3 Excision and repair synthesis 
The MutL homolog complex plays a very big role at this step of the mismatch repair. 
Similarly to the MutS homologs, the MutL homologs are also heterodimers and not homodimers as 
in prokaryotes.  Four MutL homologs identified in humans are hMLH1, hMLH3, hPMS1 and 
hPMS2. hMLH1 is the central protein interacting with either hPMS2, hPMS1 or hMLH3 to form 
hMutLα, hMutLβ or hMutLγ respectively. While the hMutLα complex is involved in the MMR 
process, the hMutLγ has been reported to play a role in cell meiosis [Li, 2008]. As described by 
Modrich (2006), the hMutLα complex is responsible for low levels of base-base and single 
nucleotides ID mutation in vitro. The specific biological function of the hMutLβ protein has not 
been described and its involvement in the MMR has not been demonstrated to date [Modrich, 2006; 
Li, 2008].  
Besides the MutL homologs, one of the proteins involved in the excision and repair 
synthesis is single-stranded DNA binding protein (RPA). The functions of RPA are to stimulate 
excision, protect the single-strand gap against endonuclease attack, and to promote resynthesis of 
the DNA [Modrich, 2006]. 
The non-histone chromatin protein PCNA (proliferating cell nuclear antigen) has also been 
reported to play multiple functions in mismatch repair. This protein confers processivity on 
polymerase δ and therefore is required for the DNA resynthesis [Modrich, 2006]. PCNA is also 
involved in the mismatch-associated DNA excision. Moreover, it has also been reported to 
participate at earlier stages of MMR by delivering MutS homologs to the DNA mismatches 
[Schofield, et al., 2003]. 
Another important protein reported to perform the posterior function is non-histone 
chromatin protein HMGB1. It has been shown that in association with MutSα HMGB1 initiates the 
mismatch-provoked excision in nuclear extracts [Modrich, 2006].  
The excision of the DNA strand containing the base mismatches, or insertion/deletion 
mispairs is performed by an enzyme exonuclease 1 (Exo1), while the repair synthesis is carried out 
by DNA polymerase  δ (Polδ) [Christmann, et al., 2003].Exo1 is a 5´-3´exonuclease. So far no 
other exonucleases have been identified in eukaryotes, although genetic and biochemical 
investigations show that exonucleases in both directions are required for eukaryotic MMR 
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[Schofield, et al., 2003]. However, as sighted by Li (2008), hMutLα possesses a PCNA/RFC (RFC-
replication factor C) dependent endonuclease activity and plays an important role in 3´nick-directed 
MMR involving Exo1. A 3´-5´exonuclease activity of Exo1 might be triggered by the PCNA/RFC 
complex. This would catalyze the degradation of the mismatch strand [Jirincy, 2006].  
The figure below is describing the strand discrimination during MMR in eukaryotic cells and 
then excision and re-synthesis. 
                  
                 
 
  
                                                                                   
 
                               
 
Figure 2: MMR in eukaryotic cells 
The figure shows two Cis/Moving models: translocation model on the left, molecular-switch in the 
middle; and a Trans/Stationary model on the right. A black point on the figure signifies the mismatch site. 
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All other participants in eukaryotic MMR mechanisms are specified. Excision and re-synthesis happens in 
either 5´-3´ (represented by black arrows), or 3´-5´direction (red arrows). Only Exo1 is involved in 5’-3’ 
direction. RPA stabilizes the single-strand gap. DNA polymerase δ binds with PCNA forming a complex in 
order to fill the gap. The strand is sealed by DNA ligase and DNA repair synthesis is completed. Both Exo1 
and RFC are involved in excision and re-synthesis in 3’-5’ direction. RPA inhibits the Exo1 once the 
mismatch is cut. Polδ fills the gap and DNA ligase seals the nick to complete the DNA repair process.  
Figure reproduced from Li, (2008) and Jiricny, (2006). 
2.3 Deficiency of the MMR genes 
The mismatch repair system plays the role of a genomic guardian by correcting the 
mismatches of the DNA. The DNA mismatch repair is also preventing both mutagenesis on the 
short run and tumorigenesis on the long. In the case of MMR deficiency spontaneous mutation rates 
are greatly elevated resulting in a “mutator phenotype”. Several studies have shown that 
inactivation of MMR is greatly associated with hereditary and sporadic human cancers [Li, 2008]. 
2.3.1 Hereditary Nonpolyposis Colon Cancer 
Germline alterations of several MMR genes cause susceptibility to Hereditary Nonpolyposis 
Colon Cancer (HNPCC), also known as a Lynch Syndrome.  HNPCC carriers inherit a mutation in 
one of the MMR gene alleles, signifying that HNPCC is a genetically heterogeneous disorder. The 
second allele either undergoes a somatic mutation or loses its heterozygoity as an early event in 
tumour development, resulting in mismatch repair deficiency [Petlomäki, 2001; Jäger, et al., 2001]. 
Conceivably this may be the cause of rapid accumulation of mutations driving tumour progression, 
[Jäger, et al., 2001].  
There are two international diagnostic criteria for HNPCC, namely “Amsterdam criteria I” 
(based on colorectal cancer), and “Amsterdam criteria II” (based on other cancers associated with 
HNPCC). Points underlying both of these criteria are: HNPCC is observed in at least two 
generations, affecting at least three relatives with HNPCC-associated cancers, one of whom is a first 
degree relative, and at least one is diagnosed before the age of 50; Familial Adenomatous Polyposis 
(FAP) is excluded, examination of tumours is pathologically verified [Brown, et al., 1998]. 
Individuals fulfilling all of the “Amsterdam criteria” are classified as typical HNPCC patients, 
while individuals fulfilling only some of the criteria are referred to as atypical patients. The 
“Amsterdam criteria I” appears to be the most important for HNPCC predisposition diagnosis, and 
usually fulfils the molecular diagnosis that requires demonstration of hereditary deficiencies in the 
MMR genes [Petlomäki, 2003]. 
Susceptible HNPCC individuals have a high risk of developing colorectal carcinoma (70-
85%), endometrial carcinoma (50%), and other carcinomas (below 15%) during their lifetime, 
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[Petlomäki, 2001]. Besides colon/rectum cancers, individuals affected by HNPCC may develop 
extracolonic malignancies at the sites of small bowel, ureter, renal pelvis, ovary and endometrium. 
Moreover, there is also a higher risk of developing hepatobiliary, brain and skin tumours for 
HNPCC affected individuals [Park, et al., 2006]. All of these carcinomas are collectively referred to 
as “HNPCC tumour spectrum”. 
As already mentioned above HNPCC predisposition may be caused by several MMR genes 
alterations.  Therefore, the HNPCC related genes vary in nature of mutation and in their expression. 
Consequently, compositions and, therefore, the activity of the mismatch repair complexes 
associated with these genes vary as well. Moreover, the HNPCC related genes are also involved in 
cellular processes other than mismatch repair, such as DNA recombination and cell cycle 
checkpoint regulation. Due to that the HNPCC associated tumour development and disease course 
varies among the HNPCC individuals [Jäger, et al., 2001]. 
2.3.2 HNPCC associated genes 
Four major MMR genes associated with HNPCC in humans are hMLH1, hMSH2, hMSH6 
and hPMS2. The germline mutations in these genes are observed in 70-80% of HNPCC families 
[Petlomäki, 2003]. More recent studies have suggested that alterations in some other genes involved 
in mismatch repair mechanisms may also be associated with HNPCC, as discussed below. 
Mutations in hMLH1 located at chromosome 3p21-p23 represent the majority of HNPCC 
cases, while the mutations in hMSH2 located at 2p16-p21 represent a large fraction of the 
remaining HNPCC cases [Li, 2008]. Usually, alterations in either one of these MMR genes result in 
typical HNPCC families fulfilling all of the “Amsterdam criteria” [Petlomäki, 2003]. Collectively 
hMSH2 and hMLH1 account for 50-60% of all mutations in typical HNPCC patients and for about 
30% in atypical HNPCC individuals [Sun, et al., 2002]. 
Other HNPCC associated mutations are found in MutL homolog genes hPMS1 (2q) and 
hPMS2 (7p), and in the MutSα homolog gene hMSH6. However, these mutations are rather rare in 
the HNPCC patients. This might be explained on the basis of the significance of protein-protein 
interaction. As shown in section 2.2 both hMLH1 and hMSH2 are essential in mismatch repair 
mechanisms. On the other hand hPMS1, hPMS2 and hPMS6 are partially redundant and/or 
dispensable. Therefore, these genes only account for the minority of HNPCC incidents [Li, 2008]. 
As noted by Petlomäki (2003), hMSH6 and hPMS2 are most likely observed in atypical HNPCC 
families, but can be detected in typical families as well. 
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Currently there are many discussions going on about implication of germline mutations in 
hMSH3 to HNPCC. Although these mutations are recognized in atypical HNPCC patients 
[Petlomäki, 2003], they have not yet been linked to HNPCC [Li, 2008].  
Germline variants in hEXO1 and polδ genes, involved in the mismatch repair process have 
also been reported. However, the association between these variations and HNPCC is also 
controversial, especially in the case with polδ for which no family studies have been shown 
[Petlomäki., 2003]. The mutations in the hEXO1 gene have been shown in atypical HNPCC 
families [Wu, et al., 2001].  
3. Family history 
 We have been provided with a medical history of one HNPCC suspected family. The 
C.1165 c>t R389W hMLH1 mutation has been found in one of the member of this family, as would 
be shown later. 
As explained in section 2.3.1 HNPCC is an autosomal dominant disorder caused by 
germline mutations of human mismatch repair genes. In autosomal dominant disorders the normal 
allele is recessive, while the defective allele is dominant. In order to understand that better we need 
to have a look at Mendelian law of inheritance. 
Although the Mendelian law might be applied to all progeny possibilities, in real cases the 
individuals carrying an autosomal dominant disorder are usually heterozygous for the allele causing 
it. Moreover, a progeny of two affected parents, especially when one of them is dominant 
homozygous, is rather rare. In the progeny of recessive homozygote (normal individual in respect to 
HNPCC) and dominant heterozygote (HNPCC-affected individual) the offspring individuals have 
equal chances of acquiring the genotypes of one of the parents. Therefore, the chance of acquiring 
HNPCC is 50% for every child.   
 Below is a pedigree chart of five generations of a real family in which some members are 
suffering from HNPCC, while others might be suffering in future. Squares represent the male 
members of the family, while circles represent the females. Squares and circles crossed over means 
that those individuals have died. Numbers appearing under each square and circle are used in order 
to identify the individuals of this particular family. Black symbols represent individuals affected by 
some conditions related to HNPCC or other cancer types. As such when a left half appears black a 
patient has been diagnosed with colorectal cancer as in the case with individuals 4 and 10. The right 
half appearing black signifies other types of cancer specified underneath, as in patient 8, who has 
been diagnosed with bladder, kidney and brain malignancies. The numbers next to each malignancy 
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diagnosis specify the age at which the patient has been diagnosed with it. When only one quarter 
appears black on the left it signifies an adenoma found in the patients colon/rectum as in patient 12.  
 
Figure 3: Family history 
A family tree of an HNPCC-related family is presented in the figure. Squares and circles represent male and 
female individuals in the family, all assigned with some number for identification. Deceased individuals are 
crossed out in the figure. Left half appearing black signifies colorectal carcinomas; left quarter - colorectal 
adenomas; right half - other distinctive carcinomas. Types of carcinomas and ages of diagnosis are specified. 
H signifies histological verification of carcinomas; J represents verification from a medical journal report; D 
– from a death certificate. 
 
The adenoma has been found under surveillance and might develop into the colon cancer in future. 
When the carcinoma tissue has been tested histologically, it is specified by a capital H, as in the 
case with patient 10. The C.1165 c>t R389W-hMLH1 mutation was found in the cells of this 
patient. Patient 12 might also be a carrier of this mutation. Yet, the patient 12 has not been tested for 
this particular mutation. When the information about cancer has been found from a medical journal 
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report it is signified by capital J (patient 8). No tumour description from pathological sight point 
was found. However, the DNA investigation of the tumour cells is possible in this case. When the 
information about patient’s cancer history has been found from a death certificate it is notified by a 
capital D, as in a case with patient 4. Most likely this patient has died of cancer that either has been 
discovered too late, or after the death. The tumour has not been removed surgically; therefore, it 
cannot be investigated. In a case when it is known that no malignancies have been found in a family 
member after its death, it is specified in the chart, as in patient 50. When no information is provided 
about the actual death cause, nothing is notified on the pedigree chart, as in case with patients 100, 
102, 3, 50-60. All of that is shown on the figure 3 below. 
4. HNPCC diagnostics 
 Here we describe different steps of the HNPCC diagnostics. In order to do so we are going 
to present a flow chart (figure 4) showing different steps of the HNPCC diagnostics. However, not 
all of the steps mentioned in this section are necessarily required for disease recognition and 
verification. Moreover, the steps of the HNPCC diagnostics are not necessarily pursued in the order 
as described below.   
4.1 Family history evaluation 
The first step of the HNPCC diagnostics is to investigate the frequency of this disease in a 
medical history of the family. This is done by making a family tree, or a pedigree chart, showing all 
HNPCC affected and unaffected members of the family. Then the family history is being 
investigated in relation to the “Amsterdam criteria I and II” that are used in order to find out 
whether or not a particular family can be classified as an HNPCC-related family (section 2.3.1). 
There are three generations affected by different types of cancer (all first-degree relatives) in 
the family presented in figure 3 (chapter 3). No information about familial adenomatus polyposis 
(FAP) in this family has been provided. Thus, FAP can be excluded. Patients 4 and 10 have clearly 
been diagnosed with colorectal cancer. Moreover, patient 10 has been diagnosed at age 43.  Patient 
8, on the other hand, has been diagnosed with three other cancer types. We also notice that one 
adenoma in the colon/rectum has been found in the patient 12. Therefore, this individual might also 
be affected by HNPCC. Based on all of these facts we can conclude that Amsterdam criteria II are 
fulfilled. Therefore, the family presented in figure 3 can be classified as the HNPCC-related family.  
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4.2 Microsatellite instability  
Sections of repeating DNA sequences called microsatellites, or simple sequence repeats 
(SSRs) are common phenomena in human DNA. The microsatellite length is very variable from one 
person to another. However, everyone has microsatellites of a specific set length. Mutations in the 
mismatch repair genes result in a failure to correct errors arising during DNA replication. Due to 
that the length of the microsatellites may change and become either shorter or longer. This 
abnormality is known as the microsatellite instability (MSI). 
In order to investigate the microsatellite instability the tumour cells DNA is compared to the 
DNA of the normal cells. Then the MSI is considered as “unstable-high” when the microsatellite 
 
Patient 
Family history
HNPCC-suspected 
(typical, atypical) 
HNPCC -not 
suspected  
No examination MSI Clinical study 
DNA 
sequencing 
IHC 
Frameshift, 
nonsense 
Protein 
function loss 
Pathogenic 
Missense 
mutations 
Functional 
assays 
Non-
pathogenic 
       Figure 4: HNPCC diagnostics 
       The flow chart of the HNPCC diagnostics is 
presented on the figure. Rectangles represent different 
steps of HNPCC diagnostics. First the patients family 
history is being evaluated on the basis of Amsterdam 
criteria I and II. If the patient is HNPCC-not suspected, 
no further examination in relation to HNPCC is 
required. If the patient is HNPCC-suspected then the 
MSI test can be performed and followed by IHC. 
Clinical studies and DNA sequencing can be done at 
both of these steps. If the DNA sequencing reveals 
frameshift, or nonsense mutations resulting in a 
truncated protein, the protein would lose its function 
and the mutation is considered as pathogenic. Yet, in a 
case of frameshift, or nonsense mutations expressing 
amino acids near the C-terminal end of the MMR 
proteins functional assays may be required (a dashed 
arrow on the figure represents this case). The functional 
assays are also required when the missense mutations 
are revealed by the DNA sequencing.  In this case the 
functional assays are used to determine the 
pathogenicity of these mutations. 
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changes are found in two out of five microsatellite regions of the DNA. When only one change is 
recognized the MSI is referred to as “unstable-low”, and when no changes are recognised the 
microsatellite is stable. 
Tumour cells with unstable microsatellites are more likely to have some mutations in one, or 
several of the MMR genes. Therefore, MSI might be considered as a first step of genetic testing and 
it is a useful tool for identifying whether or not a further analysis is necessary. However, MSI 
testing is rather suggestive than evidential, because MSI of MMR-deficient cells is not always 
unstable. Moreover, MSI of tumour cells not associated with HNPCC is usually showing some 
instability as well [Papadopoulos, 1999]. 
The degree of microsatellite instability may vary with the type of MMR gene-deficiency. As 
such, the majority of high degree MSI in HNPCC-related tumours is associated with inactivation of 
hMLH1 and hMSH2. Mutations in either one of these genes constitute the primary cause of MMR 
defects, resulting in high-degree instability of mononucleotides, dinucleotides, and other short 
tandem repeating DNA sequences [Petlomäki, 2001].    
Interestingly, occasional hMSH6 mutations result into low degree MSI [Petlomäki, 2003]. 
In this case, MutSα (hMSH2-hMSH6) correcting single base-base mismatches and short ID loops is 
inactivated. However, MutSβ (hMSH2-hMSH3) which is responsible for correcting larger ID errors 
may still be able to function [Knudsen, Unpublished]. Therefore, the presence of MutSβ may 
restore the microsatellite stability to some degree. 
On the contrary, occasional mutations in hPMS2 result into high degree instability of 
microsatellites [Petlomäki, 2003]. This might be due to the fact that MutLβ (hMLH1-hPMS1) and 
MutLγ (hMLH1-hMLH3) are not involved in the mismatch repair system to the same degree as 
MutLα (hMLH1-hPMS2). Therefore, the function of the MutLα cannot be restored. 
Additionally, hMLH3 and hEXO1 variants show variable degrees of MSI [Petlomäki, 2003]. 
4.3 Immunohistochemistry  
 Unstable microsatellites suggest that there may be some mutations in the MMR genes. In 
this case further genetic testing is appropriate. One of the techniques widely used in medical 
research and in clinical diagnosis on genetic level is called  Immunohistochemistry (IHC). This 
method is based on antigen-antibody interactions and involves localization of antigens (cellular or 
tissue constituents, such as proteins) in tissue sections by use of antibody labelling with specific 
markers, including fluorescent dyes, enzymes, or colloidal gold. The antigen-antibody binding is 
then being observed by appropriate microscopy. Radioactive elements may also be used as labels 
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and visualised by autoradiography. IHC is widely used in basic research to understand the 
distribution and localization of biomarkers and differentially expressed proteins in different parts of 
tissues. 
4.4 Clinical approach 
Clinical approach is an outcome of the HNPCC diagnostics, involving regular observations 
of the colon/rectum and other inner organs belonging to the HNPCC spectrum may be suggested to 
some individuals in suspected HNPCC families. For example regular sigmoidoscopies or 
colonoscopies may be used in order to screen the patient’s colon and rectum for abnormalities or 
cancer. This is being done in order to recognise any abnormalities at an early stage of development 
and to avoid cancer formations.  
4.5 DNA sequencing  
Another method of genetic approach in HNPCC diagnostics is the DNA sequencing of the 
MMR-HNPCC associated genes. In this method the common genes causing HNPCC are being 
sequenced in a laboratory for identification of any mutation in these genes.  
Some mutations are recognized as nonsense or frameshift mutations. They cause a 
considerable effect on the mutated protein function (in most cases protein loss of function), which is 
usually pathogenic. However, in a special occasion of frameshift or nonsense mutations expressing 
proteins near the C-terminus (represented by a dashed arrow on the diagram) a normal protein can 
still be synthesized. In this instance the protein functionality can be tested by means of functional 
assays. 
In many cases, the patients carry missense mutations of unknown significance called 
unclassified variants (UVs). These accounts for about one-third of all hMLH1-HNPCC associated 
mutations [Fan, et al., 2007b]. Distinguishing whether the missense mutations lead to the disease 
phenotype or merely represents rare variants is rather difficult [Ou, et al., 2007; Fan, et al., 2007a]. 
Therefore, the Functional assays are used to investigate whether the mutations are pathogenic, or 
normal polymorphism.  
 
4.6 Functional assays 
Functional assays as a biological and biochemical approach are used to measure a specific 
effect of the mutations. Functional assays enable to perform presymptomatic testing and to clarify 
the pathogenicity of the mutations. Aspects of MMR that are typically investigated in functional 
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assays include: synthesis of proteins, transport of proteins to the nucleus, binding abilities of 
proteins to other different protein complexes at the DNA mismatch position [Ou, et al., 2007].  
5. Functional assays of MMR proteins 
As shown in the previous section, functional assays of MMR proteins containing UVs are 
one of the criteria of HNPCC diagnostics [Ou, et al., 2007]. However, due to its complexity we 
have decided to present it in a separate chapter of the report. First the general overview of 
functional assays of MMR proteins is presented in section 5.1. Then a particular test of functional 
assays that has been used in our investigation is being introduced in more detail in section 5.2. 
5.1 General overview of Functional Assays 
Almost all of the functional assays applied to date can be divided into two main categories. 
The approach of the functional assays belonging to the first category is to test a specific MMR 
protein function including protein localization test, physical protein-protein interaction, protein-
DNA binding, and ADP-ATP cycle. The functional assays of the second category are used to test 
the MMR system as a whole network in order to investigate the ability of certain mutated proteins 
to restore the MMR system in different MMR-deficient cell lines [Ou, et al., 2007]. 
5.1.1 Tests of specific MMR protein functions 
Protein localization test: 
MMR proteins have to be transported to the site of DNA mismatch inside of a nucleus to 
perform its repair capability. Thus the subcellular location of MMR proteins is crucial for their 
functionality. The localization of MMR proteins is mainly regulated by the specific sequences of 
MMR proteins, which can interact with the nuclear import factors, translocation factors as well as 
other MMR proteins. The mutant MMR protein expressed in cells, which are tagged by 
immnostaining or by fluorescent fusion, is visible when subjecting to microscopy, thereby the 
subcellular position can be detected. Raevaara (2005) has carried out such an assay and 
demonstrated that D63E mutation of hMLH1 cannot translocate to the nucleus, thereby thought to 
be pathogenic.  
Yeast two-hybrid assay for protein-protein interaction 
Yeast two-hybrid system is based on the transcription factor protein (Gal4p) that has two 
domains. One is DNA-binding domain that binds to a specific DNA sequence; the other is 
activation domain that activates the RNA polymerase. The domains must be brought together to 
activate transcription of the reporter gene (e.g. LacZ). 
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Table 1. Summary of mismatch repair (MMR) functional assays (the table is adapted from Ou et al. 2007) 
 
Tests of specific MMR protein function (section 5.1.1) 
Intention of the functional assay Name of the functional assay Characteristics Limitations  
MMR protein subcellular 
localization test MMR protein localization assay 
Involves microscopic analysis of subcellular 
localization of fluorescent MMR proteins expressed in 
mammalian cells  
Overexpression of MMR proteins might be 
toxic and might affect proper localization. 
RNA splicing deficiency cannot be tested. 
Yeast two-hybrid assay Uses yeast two-hybrid system to evaluate physical interaction between two MMR proteins in vivo  
Only physical protein-protein interaction of 
MMR proteins is measured.  
Glutathione S-transferase (GST) pull-
down assay and IVTT  
Uses GTS pull-down and IVTT method to evaluate  
physical interaction between two MMR proteins in 
vitro 
Only physical protein-protein interaction of 
MMR proteins is measured.  
Co-immunoprecipitation and immunoblot 
assay 
Uses Co-immunoprecipitation and immunoblot 
technique to evaluate physical interaction between two 
MMR proteins in vitro 
Only physical protein-protein interaction of 
MMR proteins is measured.  
Protein-protein interaction test 
Transient expression of MMR genes in 
relevant MMR deficient cell line assay 
Involves testing the protein stability to evaluation 
interaction between two MMR proteins in vivo 
Only the stability of MMR protein is tested. 
Overexpression of MMR proteins might be 
toxic.  
Heterodimer DNA binding 
capability test DNA mobility shift assay 
Evaluates the DNA binding capacity of the MMR 
heterodimer. 
Only the DNA binding capability of MMR 
protein. Protein labeling might affect the 
DNA-protein interactions  
ATP-related test ADP-ATP cycle assay 
Tests ATPase activity, ATP binding activity, ATP-
ADP exchange and sliding clamp conformational 
change in relation to DNA binding. 
MutS proteins are the only candidate for 
this assay 
 
 
Molecular Biology Bachelor Project 
June 2008 23 
Tests of the MMR system as a whole network (section 5.1.2) 
Systems or cells Name of the functional assay Characteristics Limitations 
Expression of mutant yeast MMR genes in 
haploid yeast strains 
Expression of mutant human MMR genes 
in haploid yeast strains Yeast 
Expression of mutant yeast MMR genes in 
diploid yeast strains 
DNA mismatch repair efficiency of mutant 
human MMR proteins or the corresponding 
yeast MMR proteins are evaluated by 
monitoring the rates of spontaneous 
mutations in yeast strain. 
To minimize the errors resulting from using 
two non-identical systems, the mutations 
should localize within the evolutionary 
conserved region of both yeast and human 
genes. RNA splicing deficiency cannot be 
tested. 
Cell-free systems Cell-free in vitro MMR assays 
Cell extracts lacking a certain MMR protein 
is complemented with the mutant MMR 
protein.  DNA mismatch repair efficiency of 
this mutant MMR protein can then be 
evaluated in vitro. 
It is rather difficult to determine a proper 
concentration of the DNA with mismatch 
deficiency and the MMR proteins in vitro. 
Deficiency within the RNA splicing, protein 
stability as well as intracellular localization 
cannot be tested. 
Human cell lines Cell based in vitro MMR functional assay using a human expression system 
DNA mismatch repair efficiency of mutant 
human MMR proteins is evaluated in 
human cells. 
Human cell transfection is not always 
successful. Overexpression of MMR 
proteins might be toxic. RNA splicing 
deficiency cannot be tested. 
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The two proteins X and Y that are expected to be tested are fused with DNA-binding domain and 
activation domain respectively. Interaction of X-Y is indicated by expression of the reporter gene. 
Fan, et al. (2007b) used this assay to analyse eight missense mutations in hMLH1. They have found 
that the variants Q542L, L549P, L574P and P581L are losing their binding activity completely, 
whereas S46I, G65D, G67R, and R217C are partially losing their function. 
The glutathione S-transferase (GST) pull-down assay and in vitro 
transcription/translation (IVTT) for protein-protein interaction 
The protein X that fuses with GST is a “bait” (X-GST protein), whereas its IVTT binding 
partner, the mutated protein of interest (protein Y) is a “prey”. GST-tagged bait protein is first 
bound to an immobilized glutathione support [Ou, et al., 2007]. Then the “prey” which is labelled 
by for example 35S isotope is added. The labelled protein that interacts with the bait protein can then 
be detected. Guerrette, et al. (1999) used this assay to analyze interactions between hPMS2 and 11 
missense mutations of hMLH1. They have concluded that binding ability of L547P, K616Δ, R659P 
and A681T to hPMS2 displayed 95% reduction; whereas K618A, K618T S44F, V506A and E578G 
showed 45% to 85% reduction; and only Q524L and L582V have not been influenced. 
Co-immunoprecipitation and immunoblot assay for protein-protein interaction 
Two Flag-tagged target proteins (protein X wild type or its mutant and protein Y) are co-
expressed in cells for protein-protein interaction. The proteins in the cell lysates are 
immunoprecipitated by adding Anti-Flag antibody. The precipitates are separated by 
polyacrylamide gel electrophoresis. Immunoblots of the separated proteins are performed on a 
nitrocellulose membrane probing with anti-protein X antibody. After that they were detected with 
enhanced chemiluminescence, followed by stripping and reprobing the anti-protein Y antibody. The 
densities of the target proteins’ bands were then quantified and compared. Therefore, the difference 
of wild type X-Y interaction and mutant X-Y interaction can be measured. Sun, et al. (2002) 
performed such an assay to analyze eight hEXO1 mutant interacts with hMSH2, in which P640S, 
G759E and P770L show reduced binding capabilities. 
Transient expression of MMR genes in relevant MMR deficient cell line assay for 
protein-protein interaction 
This is the test of protein stability as an approach of testing the protein-protein interaction. 
Some MMR proteins can only be stabilized when interacting with their binding partners. On the 
other hand, if the protein’s binding partner is deficient in a certain cell line, the protein will be 
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unstable and thus undetectable. Brieger, et al. (2002) performed such an experiment to show that a 
missense mutation in MSH2 is a cause of MSH6 instability. 
DNA mobility shift assays 
Electrophoretic mobility shift assay (EMSA) can be used to measure the binding capability 
of MutSα or MutSβ heterodimers to the DNA mismatch site. The principle of this assay is based on 
translocation of the mismatched DNA oligonucleotides bonded to MutSα heterodimer. This 
complex is migrating slower through a nondenaturing polyacrylamide gel than free oligonucleotides 
[Ou, et al., 2007]. Therefore, it is very easy to clarify the DNA binding capability of the wild type 
protein and the mutated one. Clark, et al. (1999) used such an assay to test the protein affinities to 
the mismatch DNA with and without mutations. 
ADP-ATP cycle assay 
As we have seen in section 2.2, MutSα complex may function as a “sliding clamp” when 
binding to the DNA mismatch site by means of an ATP-dependent conformational change. Thus, 
the intrinsic ATPase activity, the ATP binding activity, the ADP-ATP exchange and the sliding 
clamp formation can be used to test the function of MutSα proteins with and without mutation [Ou, 
et al., 2007]. 
5.1.2 Tests of the MMR system as a whole network  
Expression of mutant yeast MMR genes in haploid yeast strains 
Based on the fact that MMR system is evolutionarily conserved in yeast cells and has some 
strong similarities with the human MHL1 protein sequences (especially in the N- and C termini), 
yeast MMR system can mimic human MMR system to a certain extent. Shcherbakaova, et al. (1999) 
used haploid yeast strains with any of the six mlh1 missense mutations that are analogous to 
mutations found in a number of HNPCC patients. They have displayed that all six mlh1 mutations 
result in reversion rate of reporter genes Lys+ and His+. Moreover, the rate of canavanine resistance 
mutation is much higher than in the wild type and is quite similar to the mlh1Δ. Therefore, they 
concluded that all six mutations thought to be pathogenic. 
Expression of mutant human MMR genes in haploid yeast strains 
Clack, et al. (2000) introduced human MSH2 genes into MSH2-deficient yeast strain, and 
showed that the human MSH2 proteins cannot function in this yeast strain. On the contrary, 
expression of either human MutSα or human MutSβ in wild type yeast strain shows an increasing 
rate of spontaneous mutations. It indicates the competitive character of mismatched DNA binding 
between human MutSα (or human MutSβ) and yeast MSH proteins. The competition blocks the 
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DNA repair system and causes a dominant mutator effect. Additionally, the mutation frequency 
caused by human MutSα is dramatically higher than by human MutSβ. Therefore MutSα is thought 
to be more important in human MMR system. Moreover, Shimodaira, et al. (1998) demonstrated 
that human MLH1 can also result in a dominant mutator effect in wild type yeast strain. 
Expression of mutant yeast MMR genes in diploid yeast strains 
Drotschmann, et al. (1999 a, b) introduced any of five yeast msh2 mutations (corresponding 
to HNPCC mutations) in one of the alleles in diploid yeast strain and showed a dominant mutator 
effect of MSH heterodimer. In this way high rate of spontaneous mutation can be monitored.  
Cell-free in vitro MMR assays 
Certain proteins lacking in the extracts of the MMR deficient cell line are replaced with the 
same proteins containing the mutation of interest. Artificial mismatch substrates can be repaired if 
the MMR system can be restored by added proteins. The mismatches in the artificial substrates can 
be designed in the way that the repaired mismatches are within specific recognition sequences of 
certain restriction enzyme. Li, et al. (1995) used this assay to demonstrate that protein extracts of 
H6 cells (a MLH1 defective cell line), which is complemented with human hMutL (MLH1 and 
PMS2) restore the MMR capability. Nystrom-Lahti, et al. (2002) showed the same in vitro method 
to analyze a number of hMLH1 mutations in HNPCC patients. 
Cell-based in vitro MMR functional assay using a human expression system 
Torjan, et al. (2002) used human MLH1 defective cell line 293T as the model system. The 
cell is MLH1 promoter-methylated with unstable PMS2. They expressed the MLH1 mutant and 
PMS2 wild type in the cells by transient transfection. Cell extracts have been incubated with 
bacteriaphage M13 DNA that has a mismatch in LacZ gene. Then the recombinant DNA has been 
transformed into competent E.coli cells. The MMR efficiency can then be detected by the number 
and colour of the plaques after incubating the cells on an X-gal plate. Although the human cells are 
complicated systems and somehow difficult to transfect, so far it is the best model system of MMR 
functional assay from an evolutionary conservational point of view. 
5.1.3 Functional Assays uncertainties 
All the functional assays described in this chapter are methods to analyze the MMR protein 
function. However, the UVs with functional MMR proteins may still have MMR deficiency. For 
example the variation of mRNA splicing or RNA instability can also result in MMR defects. 
Therefore, even though when all the functional assays are normal, we cannot directly conclude the 
mutation is nonpathogenic and merely a rare polymorphisms [Ou, et al., 2007]. 
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5.2 Nuclear translocation of MMR proteins 
As we have already mentioned in the previous chapter, the functional assays of MMR 
proteins are carried out on the basis of protein-protein interaction, DNA binding ability and MMR 
repair capability.  Yet the subcellular localization of MMR proteins is the precondition for the 
proficiency of MMR proteins. The MMR-dependent correction of replication error requires nuclear 
import of MMR proteins. Due to that we have decided to investigate this particular functional assay.  
Proteins can be transported from cytoplasm to nucleus via nuclear pore complexes (NPC). 
Low molecular weight proteins (<60Da) can pass through NPC by concentration-dependent passive 
diffusion. However, NPC only admits high molecular weight proteins that are shepherd by specific 
transport receptors that can be recognized [Knudsen, et al., unpublished]. Nuclear localization 
signal (NLS) in the protein is requisite of the cargo binding to the transport receptor [Fried, et al., 
2003].  NLS that usually consists of one or more positively charged clusters of lysines or arginines, 
typically existing in the form of monopartites (e.g. PKKKRKV), or bipartites (e.g. 
KRPAATKKAGQAKKKKLDK) [Brieger, et al., 2005]. Nuclear translocation of proteins is an 
energy requiring process, which is driven by converting RanGTP in the nucleus to RanGDP in the 
cytoplasm with the cooperation of transport receptor importin α/β. In the cytoplasm, the cargo 
protein with NLS binds to importin β indirectly by the aid of adaptor protein importin α. The 
trimeric complex (NLS-protein/ importin α/ importin β) is then directed to NPC that can interact 
with the specific recognition sequence in importin β [Fried, et al., 2003]. Afterwards, the complex 
enters the nucleus through the NPC channel. In the nucleus, RanGTP binds importin β inducing 
cleavage of the trimer. Eventually the cargo protein is translocated into the nucleus. The RanGTP 
bound importin β as well as CAS/RanGTP bound importin α return to the cytoplasm through the 
NPC. Hydrolysis of RanGTP in the cytoplasm releases importin α and importin β for running a new 
cycle of cargo protein nuclear translocation. Besides this classical nuclear translocation route, 
proteins without NLS can also be imported into the nucleus by means of the so-called 
“piggybacking”, namely, by binding with a NLS-proficient protein [Knudsen, et al., unpublished]. 
Seven different nuclear transport factors including six different importin α and one importin β are 
identified to date.  
A number of studies of the nuclear translocation of MMR proteins have been carried out. 
MutSα consisting of hMSH2 and hMSH6 is essential to recognize the mismatches. In vitro study 
shows that hMSH2 that does not have NLS can interact with importin α1 but not with α3 or α7 
[Knudsen, et al., unpublished]. Dimerization of hMSH2-hMSH6 is thought to enhance nuclear 
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import of hMSH2. Expression of two hMSH2 mutants (P622L and C697F) associated with HNPCC 
in mouse fibroblast cells is reported to show insufficient nuclear translocation in comparison with 
hMSH2 wild type [Knudsen, et al., unpublished]. Moreover, phosphorylation of hMSH2 and 
hMSH6 is also suggested to play an important role in posttranslational modification and nuclear 
localization of MutSα [Knudsen, et al., unpublished].  
MutLα, a heterodimer of hMLH1-hPMS2, is essential for MMR. Recent study has found 
that hMLH1 contains a cluster of NLS sequences (469 PRKRH 473) and can form a complex with 
importin α1, 3, 7/β [Knudsen, et al., unpublished]. Another cluster of NLS-like sequences in 
hMLH1 (496 PRRR 499) is shown to have no relation to nuclear localization [Brieger, et al., 2005]. 
hPMS2 with monopartite NLS sequences (574 PNTKRFK 580) can bind to importin α1/β. NLS 
sequence mutation in either hMLH1 or hPMS2 results in decreased nuclear import of both 
monomers [Knudsen, et al., unpublished]. It is suggested that MLH1 and PMS2 are co-imported in 
nucleus in the form of MutLα compelx, as the dimerization leads to uncover the NLS sequences in 
both monomers [Knudsen, et al., unpublished]. A number of HNPCC-related hMLH1 mutants 
(D63E, G67R, L155R, V185G and R659P) are reported to show a decreased nuclear localization as 
well as impaired PMS2 binding capability [Raevaara, 2005].  
hEXO1, another important MMR protein, containing a functional NLS sequences 418KRPR 
421 can bind to importin α1, 3, 7/β [Knudsen, et al., unpublished]. It was suggested that the nuclear 
localization of hEXO1 is closely related to the intracellular expression of hMLH1 and hMSH2 
[Knudsen, et al., unpublished]. 
6. Distribution of hMLH1 mutations 
The functional domain of the hMLH1 protein mutations associated with HNPCC is being 
introduced in this chapter of the report. 
Recent studies have classified the MLH1 protein into four different domains. An amino 
terminal domain (corresponding to the amino acids 1-350) includes four ATP binding and 
hydrolysis motifs (residues 31-43, 63-68, 97-107,146-147) [Raevaara, 2005]. A linker domain or 
the N-terminus domain (corresponding to amino acids 350-500) contains putative nuclear 
localization signals (469PRKRH473) [Brieger, et al., 2005]. A carboxyl terminal (C-terminal) domain 
(corresponding to amino acid 492-743) is responsible for the interaction with PMS2 [Raevaara, 
2005]. A so-called carboxyl terminal homology domain (CTH) (corresponding to the amino acids 
744-756) is suggested to promote the interaction with PMS2 and to enhance PMS2 stability [Mohd, 
et al., 2006]. All of these domains are presented on figure 5 below. 
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Figure 5: A schematic illustration of functional domains of MLH1  
The hMLH1 protein domains shown on the figure are: N-terminus domain, linker domain, C-
terminus domain and CTH. These domains are shown in green, blue, red and black colours respectively. The 
ATP binding and hydrolysis motif is shown in grey and appears within the N-terminus domain. The NLS is 
represented in yellow colour and can be found within the linker domain.  
 
According to the InSiGHT database (http://www.insight-group.org/), the majority of 
pathogenic hMLH1 alterations are situated in the region of amino terminal and carboxyl terminal 
domains, indicating the essential function of these two domains on the proficiency of hMLH1. 
Mutations in N-terminus 
The MutL homologs belong to the family of GHKL ATPase including DNA gyrase b, 
HSP90, and histidine kinases. In E.coli, MutL that can bind and hydrolyze ATP was suggested to 
clamp on DNA by the ATP-dependent N terminal dimerization [Raevaara, 2005; Räschle, et al., 
2002]. In human cells, binding and hydrolysis of ATP might lead to a conformational change in the 
N-terminus of hMutLα. Therefore, it is very essential for the stability and proficiency of the 
heterodimer [Räschle, et al., 2002]. Thus, alternations in the N-terminus of MLH1 can impair the 
ATP binding, hydrolysis capability and the stability of MLH1. Consequently, PMS2 is degrading 
when MLH1 is not stable. In vitro studies on mutation MLH1-P28L, MLH1-D63E, MLH1-C77R 
demonstrate that mutations in amino terminal domain of MLH1 may cause the instability of MLH1 
as well as PMS2, and result in defective MMR [Raevaara, 2005; Räschle, et al., 2002]. 
Mutations in C-terminus  
Mutations in the C-terminus of MLH1 may also lead to instability of protein as a result of 
structural alteration in the polypeptide. Raevaara (2005) has performed immunoblot assay on eight 
MLH1 variants with C-terminus alteration expressed in 293T human embryonic kidney cells 
(hMLH1-deficiency due to promoter methylation) to demonstrate such a phenomenon. Moreover, 
mutation in the C-terminus of MLH1 may cause problems in the subcellular localization of protein 
by affecting the dimerization of MLH1 and PMS2. Unbound C-terminus of MLH1 is suggested to 
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limit the nuclear import in the manner of masking NLS [Wu, et al., 2003]. On the other hand, 
MLH1 and PMS2 C-terminal dimerization is thought to expose the NLS and ensure the nuclear 
import of both proteins. A number of HNPCC associated C-terminal MLH1 mutations R618A, 
L550P, A589D and P648L have been demonstrated to have problems in dimerization with PMS2 as 
either one of the proteins or both proteins fail to import into the nucleus [Wu, et al., 2003; Raevaara, 
2005]. 
Mutations in CTH 
CTH in MLH1 is suggested to increase the stability of MutLα, but is not critical for the 
interaction between MLH1 and PMS2. On the contrary, truncation of the CTH decreases the 
stability of the heterodimer [Mohd, et al., 2006]. Point mutations in CTH such as K751R and 
R755W are shown to be pathogenic due to MMR deficiency caused by some reasons other that 
PMS2 instability [Mohd, et al., 2006].  
Mutations in NLS 
As we mentioned in the previous chapter, NLS is crucial for nuclear import of the protein as 
the NLS-protein can bind to importin α/β and subsequently enter the nucleus through NPC. 
Obviously, mutations in NLS of hMLH1 will affect the nuclear localization of hMLH1 protein. A 
number of missense mutations in NLS of hMLH1, especially the mutations at K471 and R472, 
mostly show the cytoplasmic localization. This indicates an impaired nuclear translocation of 
MutLα [Brieger, et al., 2005]. Moreover, mutations in NLS of hMLH1 have no effect on interaction 
with hPMS2 [Brieger, et al., 2005]. However, according to InSiGHT database, no HNPCC 
associated NLS mutation in hMLH1 has been reported to date. Additionally, some mutations 
happenening at the position other than NLS shows similar consequences. In particular hMLH1-
K84E mutation, critical for nuclear import of hMLH1, is suggested to function similarly to NLS of 
hMLH1 [Raevaara, 2005]. 
Mutations in linker domain other than NLS 
HNPCC associated mutations in the linker domain are very rare, which might be due to the 
functional nature of this domain. Some mutations in the linker domain act as nonpathogenic 
polymorphisms. For example, hMLH1-V384D and hMLH1-K443Q are considered to be 
nonpathogenic mutations as shown in some recent studies [Wang, et al., 1998; Raevaara, 2005]. 
Some mutations in the linker domain show mild pathogenicity due to their impaired repair 
efficiency. (e.g. hMLH1-H329P has about 30% repair efficiency in comparison to hMLH wild type) 
[Raevaara, 2005]. Moreover, mutations in the linker domain could also show a strong pathogenicity. 
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This could result from changes in protein structure, especially when the amino acid changes are 
nonconservative. Fan, et al. (2007b) have demonstrated that hMLH1-V384D shows extremely low 
repair efficiency. Valine (a neutral nonpolar amino acid) changing to aspartate (a negatively 
charged acidic amino acid), is thought to change the polarity of the residue and thus the structure of 
hMLH1 protein. Additionally, pathogenic mutations in linker domain of hMLH1 may also be 
caused by incorrect RNA splicing. 
7. Methodolgy 
 In this chapter we are going to introduce the procedure of our experiment. Generally the 
procedure can be divided into six steps, as illustrated below. 
7.1 Site-directed mutagenesis 
 First the site-directed mutagenesis has been carried out with the purpose of designing and 
preparing the primers for further investigation. 
7.1.1 C.1165 c>t  mutation 
We have been provided with the information that the patient 10 (figure 1) has a c→t 
mutation at  nucleotide position 1165 coding for hMLH1-R389W protein, suspected to be 
responsible for the hMLH1 inactivation during the mismatch repair pathway. Due to that we have 
designed a primer pair with this particular mutation in order to investigate and evaluate its function 
based on subcellular localization.  
7.1.2 Primer design 
 The primer pair complementary in reversible direction and carrying the mutation has been 
designed as shown below: 
Primer 1 (5′-3′): ggttcgtacaga ttcctgggaa cagaagcttg 
Primer 2 (5′-3′): caagcttctg ttcccaggaa tctgtacgaacc 
The nucleotide mutations are marked in both primer sequences. These primers have been provided 
from “Invitrogen”. It has been calculated that the temperature of denaturation (Tm) is about 78°C 
for both primers. 
 
7.1.3 Vector design 
Three different vectors have been used at different steps in this investigation. These vectors 
are presented in a table below. 
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Name Common name Expression Source Resistance 
pEYFP Empty vector Yellow fluorescent proteins (YFPs) 
Provided by 
“Clontech” 
Resistance to 
Kanamycin 
pEYFP-hMLH1 Wild type vector 
YFP-hMLH1 fusion 
proteins 
Provided by  
PhD Anna 
Lützen (hMLH1 
is cloned into 
pEYFP between 
RcoR1 and 
BamH1 sites ) 
Resistance to 
Kanamycin 
pEYFP-hMLH1-
R389W 
Mutant type 
vector 
YFP fused with 
hMLH1 carrying 
the mutation 
R389W 
Created by site-
directed 
mutagenesis 
Resistance to 
Kanamycin 
7.1.4 PCR replication 
As we can see from a table above the mutant type vector (pEYFP-hMLH1-R389W) is 
created by the polymerase chain reaction (PCR). This is being done by first denaturating the wild 
type plasmid (pEYFP-hMLH1) into two separated template strands. Then the primers hybridise to 
the separated strands and the DNA between them is being synthesized. As a result two new double 
stranded templates are produced. In such a way the desirable DNA plasmid is being amplified 
exponentially with every PCR cycle. Our PCR reaction has been run for 12 cycles. The following 
chemical reagents have been used: 
• 10 ng/µl pEYFP-hMLH1 template 
• dd H2O double distilled water 
• 62.5 ng/µl primer 1 
• 62.5ng/µl primer 2 
• 10*pfuUltra buffer 
• pfuUltra polymerase 
• dNTP 10mM 
Two Eppendorf tubes have been prepared and the reagents have been added according to the table:  
Tube Primer 1 Primer 2 Buffer Polymerase dNTP dd H2O dd H2O Template
1 2µl 2µl 5µl 1µl 1µl 36 µl 4µl --- 
2 2µl 2µl 5µl 1µl 1µl 36 µl --- 4µl 
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7.1.5 Digestion of the products 
1µl of DPn I (10U/µl) restriction enzyme is added to the amplication products. After 1 
minute centrifugation, the mixture incubates for about 1 hour at 37°C. So the parental DNA is 
digested. 
7.2 Transformation 
In order to check whether the site-directed mutagenesis has worked successfully the 
transformation experiment is preceded. First the competent cells are prepared. Then the plasmid 
transformation of the competent cells is carried out and plated on LB and kanamycin plates. Both 
wild type (pEYFP-hMLH1) and mutant type plasmids (pEYFP-hMLH1-R389W) have kanamycin 
resistance. Therefore, if the site-directed mutagenesis is successful the colonies should be observed 
on the plates. 
7.2.1  Competent cells preparation 
1) The overnight culture containing 5 ml LB and E.coli (TOP 10) has been prepared in 37°C water 
bath. 
2) 4 ml of the overnight culture have been poured into 100ml LB and incubated for 1,5 hours at 
room temperature until OD value is about 1,2. 
3) 2 tubes containing 40 ml culture was centrifuged in the Jouan refrigerated centrifuge at 4°C and 
4200rpm for 15 min. 
4) After the centrifugation the supernatant liquids were poured out. The cells were resuspended in 
16ml 10mM MgSO4. 9ml of content from each tube were centrifuged for 20min at 4200 rpm. 
5) The supernatants containing MgSO4 were discarded. The cells were resusponded in 16ml 50mM 
CaCl2 and incubated on ice for 30 min.  
6) After that the mixtures were centrifuged again for 20 min at 4°C and 4200 rpm. The 
supernatants were poured out and 2ml of 50mM CaCl2 were added. The cells were re-suspended 
and incubated on ice for an hour. As a final result the cells became competent. 
7.2.2 Plasmid transformation 
1 LB plate and 3 LB+kanamycin plates have been prepared. 4 Eppendorf tubes were 
prepared as shown in the table below.  
 
 
 
Molecular Biology Bachelor Project 
June 2008 34
No. dd H2O 
Wild type 
plasmid 
(pEYFP-
hMLH1) 
Mutant type 
plasmid  
(pEYFP-hMLH1-
R389W) 
plate Colony counts 
1 10µl --- --- LB Many 
2 10µl --- --- LB+kanamycin No colony 
3 --- 10µl --- LB+kanamycin Many 
4 --- --- 10µl LB+kanamycin Many 
 
1) 200 µl of competent cells were added to each tube and mixed by hand shaking. After that the 
mixtures were incubated first on ice for 30 min and then in a 40°C water bath for 5 min. 
2) 1 ml of LB medium was added to each tube followed by incubation in 37°C water bath for 
about 90 min. 
3) The contents in the tubes were then spread on the plates as shown in the table. After that, they 
were incubated overnight at 37°C. Next day the colonies on the plates were counted and noted 
in the table above. At last, the plates were put in a 4°C fridge for a long-time storage. 
7.3 Mini plasmid DNA preparation (NucleoSpin® plasmid kit provide by 
Macherey-Nagel) 
As the plasmid transformation has shown the mutant type vectors (pEYFP-hMLH1-R389W) 
have a resistance to kanamycin, indicating that the site-directed mutagenesis seems to be successful. 
Next, in order to increase the number of plasmids the mini plasmid DNA preparation procedure was 
followed. This procedure involves introduction of plasmids into E. Coli cells and then growing 
these cells until reaching a desirable number. After that the plasmids are extracted from the E. Coli 
cells.  
7.3.1 Overnight cultures preparation  
The overnight culture has been prepared by using single colonies grown on freshly streaked 
plate No. 4 (section 7.2.2). That was done in the following way: 
1) 5 tubes containing 5 ml LB and 100 µg/ml of kanamycin were prepared and marked 0-4. 
2) 4 colonies from plate 4, prepared in the previous step of experiment (section 6.2.2), have been 
re-streaked onto a new plate (plate 5), which has been divided into 4 parts.  
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3) One single colony from each part has been inoculated in tubes 1-4. No colonies were put in tube 
0 in order to make a control. 
4) All tubes have been incubated in 37°C water bath overnight. 
7.3.2 MiniPrep procedure 
1) 4 Eppendorf tubes have been marked 1-4. 2 ml of the overnight cultures were poured into the 
tubes with the corresponding numbers. The cells were micro-centrifuged for 30 sec at 11,000*g. 
the supernatant liquids have been discarded, leaving only the pellets in the tubes. 
2) Other 2 ml overnight cultures have been added to the same tubes with the corresponding 
numbers. The cells were micro-centrifuged and discarded of the supernatants again. 
3) 250µl of re-suspension buffer A1 has been added to each tube and the cells were re-suspended 
with a use of a pipette. 
4) 250µl of lysis buffer A2 were added. The tubes have been closed and inverted 6-8 times and 
then incubated at room temperature for about 5 min. 
5) 300µl of neutralisation buffer A3 has been added to each tube. The content in the tubes has been 
mixed by inverting 6-8 times. The tubes were then centrifuged for 5 min at 11,000*g. 
6) 4 NucleoSpin Plasmid Columns have been placed in a Collection tube. The supernatants from 
step (5) have been loaded onto the columns. Then the columns have been centrifuged for 1 min 
at 11,000*g. the flow through has been discarded.  
7) 500µl of wash buffer AW has been added and centrifuged for 1 min at 11,000*g. Then 600µl of 
A4 buffer was added and centrifuged for 1 min at 11,000*g again. The flow-through has been 
discarded. 
8) The tubes have been centrifuged for 2 min at 11,000*g and the flow-through has been discarded 
again. 50µl of elution buffer AE has been added to each column. Then the columns were 
incubated for 1 min at room temperature and centrifuged for 1 min at 11,000*g. The plasmid 
DNA has been collected. 
9) At last the DNA concentrations and the purity indexes (OD260/OD280) were measured by Nano 
Drop ND-1000 Spectrophotometer. The results of these measurements are presented in a table 
below. 
No. of tube Concentration OD260/OD280 
1 508.8 ng/µl 1.87 
2 412.5 ng/µl 1.88 
3 486.7 ng/µl 1.88 
4 550.6 ng/µl 1.86 
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7.3.3 DNA sequencing 
Plasmids (pEYFP-hMLH1-R389W) obtained by the mini plasmid DNA preparation were 
sent to “DNA-Technology A/S, Denmark” for the sequence analysis. The sequence of the mutant 
plasmid (pEYFP-hMLH1-R389W) has shown to be correct. Moreover, it was the only mutation 
found in the plasmids, indicating that the mini plasmid DNA preparation has been successful. 
7.4 Maxi plasmid DNA preparation (NucleoBond® Xtra plasmid purification kit 
provide by Macherey-Nagel) 
After checking the sequence of the pEYFP-hMLH1-R389W plasmids the maxi plasmid 
DNA preparation was carried out. That was done to prepare a greater amount of the mutant 
plasmids (pEYFP-hMLH1-R389W) in order to carry out plasmid transfection in a later step of the 
experiment. 
7.4.1 Overnight cultures preparation 
1) First a starter culture has been prepared by inoculating a single colony from plate 5 (section 
6.3.1) in 5 ml LB medium. 5 µl of kanamycin have been added. Then the starter culture has 
been incubated in a 37°C water bath for about 8 hours. 
2) Then the starter culture was diluted 1:1000 in 300 ml LB containing kanamycin and incubated 
in a 37°C water bath overnight. 
7.4.2 MaxiPrep procedure 
1) First OD600 of the overnight culture was measured and desirable culture volume was calculated 
by the formula: 
V(ml) = 1200/OD600 =1200/2,34 = 512,8 ml 
2) The cells were pellet in “Jouan” centrifugation apparatus at 4°C and 4200 rpm for about 10 min. 
Then the supernatant was discarded and the cells have been re-suspended in 24 ml resuspension 
Buffer+RnaseA with a use of a pipette. 
3) 24 ml of lysis buffer LYS have been added to suspension and inverted 5 times. Then the mixture 
has been incubated for about 5 min at room temperature. 
4) A filter was placed on the top of a NucleoBond Xtra column. Then 50 ml of equilibration buffer 
EQU were loaded on the rim of the column filter. 
5) 24 ml of the neutralising buffer NEU were added to the suspension. Then the tube was inverted 
15 times and the lysate was immediately loaded on the column filter. 
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6) 30 ml of the equilibration buffer EQU were loaded on the rim of the column filter. Then the 
filter was discarded from the column and the column was washed with 50 ml WASH buffer. 
7) The column was eluted with 30 ml elution buffer ELU. Next all of the eluate has been collected 
in 50 ml centrifuge tube. 
8) 21 ml of isopropanol were added to the eluate and mixed well. The tube was then left for about 
2 min to let the eluted plasmid DNA to precipitate. 
9) A plunger from a 30 ml syringe has been removed and a NucleoBond Finalizer has been 
attached to the syringe outlet. The eluate mixture from (8) has been poured into the syringe. 
Then the plunger has been inserted back into the syringe and the mixture was pressed through 
NucleoBond Finalizer in order to discard the flow through. 
10) NucleoBond Finilizer has been removed from the syringe, the plunger has been pulled out and 
then the NucleoBond Finilized has been reattached to the outlet. 10 ml of 70% ethanol have 
been filled into the syringe. The plunger was inserted back into the syringe and the ethanol has 
been discarded from the flow through of the syringe. 
11) The filter membrane of the NucleoBond Finilizer attached to the syringe outlet has been dried 
out by pressing air through the syringe for 6 times. Each time the NucleoBond Finiliser has been 
removed from the outlet prior to plunger pulling out. 
12) A plunger of a 1ml syringe has been pulled out and a NucleoBond Finilizer from (11) has been 
attached to the syringe outlet. The NucleoBond Finilizer outlet has been placed above a fresh 
collecting tube. 1ml of TE buffer has been filled into the syringe Then the plunger has been 
inserted back into the syringe and pressed through in order to elute plasmid DNA. 
13) NucleoBond Finilizer has been removed from the 1 ml syringe and the plunger has been pulled 
out. The NucleoBond Finiliser has been reattached to the outlet. Then the eluate collected in the 
tube has been transferred back into the syringe. The plunger was inserted back into the syringe 
and pressed through in order to elute the plasmid DNA into the same collecting tube for a 
second time. 
14) At last the DNA concentration of 2650.9 ng/µl of the eluate has been measured by Nano Drop 
ND-1000 Spectrophotometer. 
7.5 Transfection 
The DNA prepared by Maxi Preparation described in the previous section has been 
transfected into the human colon cancer cells in order to investigate hMLH1 localization. The basic 
principles behind the DNA transfection are explained in appendix I 
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7.5.1 Cell lines 
Two human colorectal carcinoma cell lines have been used in this part of the experiment. 
The first cell line is HCT116 (hMLH1-defficient), notably known for having a homozygous 
mutation in the MMR gene hMLH1 on chromosome 3 damaging to the MMR activity. 
 Another cell line is HCT116+chr 3 (hMLH1-proficient). This line is the HCT116 with an 
extra chromosome 3 (from normal fibroplasts), which restores the MMR activity.  
7.5.2 Transfection procedure 
1) Each cell line has been cultured on a “Costar” 6 well plate with lid with the arrangement in two 
rows and three columns. In order to achieve a good DNA transfection the cells have been 
cultured in two concentrations. 150,000 cells have been cultured in the first raw wells and 
200,000 cells in the second raw wells.  
2) The cells were grown in each well in 2 ml McCoy’ s 5A medium (Invitrogen) supplemented 
with supplePen/Strep medium that prevents bacterial growth. 10% Fetal Bovine Serum (FBS) 
has been added to the medium to provide nutrients essential for the cell proliferation and growth. 
3) Prior to the transfection experiment the Pen/Strep medium has been removed from the wells and 
substituted with 2ml OptiMem medium. Two tubes containing 50 µl of the OptiMem medium 
have been prepared. Then 1µg of the MaxiPrep DNA (pEYFP-hMLH1-R389W) has been added 
into one of the tubes, while 5µl of lipofectamine have been added to the other.  
4) After incubating both tubes for 5 min at room temperature the content of the tube containing 
lipofectamine has been poured into the other tube. 
5) After 35 min incubation at room temperature the content in the tube has been spread into one 
column on each plate in equal amount.  
6) Steps 4-6 have also been carried out with the wild type vector (pEYFP-hMLH1) and the empty 
vector (pEYFP), so that by the end of this procedure all three vector types were spread in one of 
the column on each cell line plate.  The plates were then put in 37°C incubator overnight. 
7.5.3 Fluorescent microscopy  
After about 18 hours of incubation the cells have been observed with the help of a 
fluorescent microscopy. As we have seen transfection has turned to be more efficient in the wells 
containing 200,000 cells. Therefore only these wells have been investigated more closely. 
Fluorescent photographs of each of the wells have been taken under the visible light, under the UV 
light and then under both of lights. The zoomed-in images of these photographs are presented in the 
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next chapter, while the full images can be found in appendix II. The magnification is 10 times for 
all of these images. The table below shows the results of the full image photographs in appendix II.  
 
Cell line HMLH1-deficient HMLH1-proficient 
Type of 
light 
Empty 
vector 
(pEYFP) 
Wild type 
DNA 
(pEYFP-
hMLH1) 
Mutant 
DNA 
(pEYFP-
hMLH1-
R389W) 
Empty 
vector 
(pEYFP) 
Wild type 
DNA 
(pEYFP-
hMLH1) 
Mutant 
DNA 
(pEYFP-
hMLH1-
R389W) 
Background 
light 1 4 7 10 13 16 
UV light 
 2 5 8 11 14 17 
Background 
and UV 3 6 9 12 15 18 
8. Results & Analysis 
The experimental procedure has been introduced in the pervious chapter. Human HCT116 
(hMLH1-deficient) in parallel with human HCT116+chr 3 (hMLH1- proficient) cell lines have been 
transfected and observed under the power of a microscope. Next, the pictures of the cells have been 
taken as explained in section 7.5.3. Here we present and analyze the results of the fluorescent 
microscopy. Figure 5 below shows the images of (a) the hMLH1-deficient cells, while (b) 
represents the images of the hMLH1- proficient cells.  
Figure 5: Fluorescent microscopy of DNA transfected cells 
(a) Zoomed in images of the hMLH1-deficient cells 
Type of DNA Background light UV light Background + UV 
Empty vector 
(pEYFP) 
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Wild type DNA 
(pEYFP-hMLH1) 
Mutant DNA (pEYFP-
hMLH1-R389W) 
 
 
(b) Zoomed in images of the hMLH1- proficient cells 
Type of DNA Background light UV light Background + UV  
Empty vector 
(pEYFP) 
 
Wild type DNA 
(pEYFP-hMLH1) 
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Mutant DNA 
(pEYFP-hMLH1-
R389W) 
 
 As the figure above shows the pictures of empty vectors (pEYFP), wild type (pEYFP-
hMLH1) and mutant type DNA (pEYFP-hMLH1-R389W) of both cell lines have been observed 
under the background light (visible light), the UV light and finally both background and UV lights 
alone. Although only the zoomed in images appear in the figure 5, the total image photographs can 
be found in appendix II. It is necessary to notice that the zoomed in images that are from same 
places of each three photographs under different lights have been selected in the best possible way. 
However, the image of the hMLH1-deficient cells transfected with the mutant DNA (pEYFP-
hMLH1-R389W) is different under the UV-light than under the background and background+UV 
lights due to a difficulty of identification of the cells. 
 The background light images have been taken for two reasons: in order to investigate the 
functioning of the cells and to detect any apoptotic cells that appear as spherical and highly 
luminous objects. By looking at the UV images we can investigate the localization of the yellow 
fluorescent proteins.  This is done by observing whether the staining is in the nucleus, in the 
cytoplasm, or not in the cell. However, in this case it might be difficult to distinguish the apoptotic 
cells from the living cells. Due to that the background images can be complimented to the UV 
images. Moreover, the photographs taken under the background plus UV lights showing both clear 
profile of the cells and the localization of the fluorescent staining can be investigated. 
 Generally, by looking at the photographs in appendix II, and at the zoomed in images 
presented in the figure 5 above the following observations can be made:  
(a) HMLH1-efficient cell line 
Staining of the empty vector (pEYFP) appears to be inside of the cells as shown on the UV and 
on the background + UV images. 
As we look at the cells transfected with the wild type DNA (pEYFP-hMLH1), it becomes clear 
that transfection has not turned to be successful. The intracellular staining is not present. 
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Transfection with the mutant DNA (pEYFP-hMLH1-R389W) seems to be very efficient. The 
staining appears to be in the nuclei of the cells. 
(b) hMLH1- proficient cell line 
Similarly to the HCT116 cell line staining in the empty vector (pEYFP) appears to be inside of 
the cells, but not in the nuclei.  
Staining of both the pEYFP-MLH1 wild type and pEYFP-MLH1-R389W appears to be in the 
nuclei of the cells. That is clearly seen on the UV photographs. However, the clarity of the images 
does not seem to be very good. 
9. Discussion 
As noted earlier in the report the hMLH1 protein is inactivated in the HCT116 cell line due 
to a homozygous mutation of this gene on chromosome 3 [Koi, et al., 1994]. This results in the 
endogenous PMS2 instability of this cell line.  
When empty vectors (pEYFP) are transfected in the hMLH1-deficient cells, only the yellow 
fluorescent proteins (YFPs) are expressed. These proteins cannot enter the nucleus because they do 
not contain the NLS. Instead, they diffuse into the cytoplasm. This is identified by the yellow 
fluorescent colour in the cells on the UV photographs. The same observation is made in the 
hMLH1-proficient cell line transfected with empty vector (pEYFP). Although both hMLH1 and 
PMS2 are present in this cell line due to the insertion of an extra chromosome 3, the YFPs are not 
fused with the endogenous MutLα complex that localizes in the nuclei of cells. Consequently, the 
staining is seen in the cytoplasm, rather than in the nucleus of hMLH1-proficient cells. 
In principle, the wild type DNA (pEYFP-hMLH1) transfection in both hMLH1-deficient 
and -proficient cells should lead to expression of YFP-fused hMLH1 protein. It has been suggested 
that hMLH1 wild type can localize in the nuclei of the cells by either co-tranlocation with hPMS2 
[Wu, et al. 2003] or just by itself [Raevaara, 2005]. Subsequently, due to the YFP-fused hMLH1 
protein the fluorescent staining should be seen in the nuclei of the cells. Unfortunately, this 
observation has been demonstrated only in the hMLH1-proficient cells. As it has been shown in 
chapter 8 the wild type DNA (pEYFP-hMLH1) transfection in the hMLH1-deficint cell line has not 
been successful. However, in our opinion the result of the wild type DNA (pEYFP-hMLH1) 
transfection in the hMLH1-deficient cells should be qualitatively the same as demonstrated in the 
hMLH1-proficient cells. This might be due to two reasons. 
First of all, if YFP-hMLH1 can only enter the nucleus of the cell in complex with hPMS2, 
then it has to interact with the endogenous hPMS2. A similar experiment performed by Wu, et al. 
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(2003) suggests that stability of endogenous hPMS2 and the formation of MutLα in hMLH1-
deficient cells should be restored by transfection after about one day. Moreover, we have to notice 
that the level of detectable hMLH1 nuclear staining in hMLH1-proficient cells can be affected by 
the competitive relationship between endogenous hMLH1 and YFP-fused hMLH1 to 
heterodimerize with hPMS2. However, in our opinion this effect is not so significant in our 
experiment, as the YFP-fused MLH1 is overexpressed in the cells. 
Secondly, if YFP-hMLH1 can enter the nucleus just by itself, the NLS of YFP-hMLH1 may 
still be functional or partially functional without interacting with hPMS2. What is more, the 
overexpression of YFP-hMLH1 may also contribute to its nuclear translocation.    
In the mutant type DNA (pEYFP-hMLH1-R389W) transfection experiment, the localization 
of fluorescent staining is compared with the result of the wild type DNA (pEYFP-hMLH1) 
transfection. As shown in chapter 8, clear staining is found in the nuclei of the cells in both 
hMLH1-deficient and –proficient cell lines, which might be similar to the wild type. Based on this, 
we suggest that hMLH1-R389W might still have the same function in nuclear import and 
localization as the wild type. Of course, single experiment of the nuclear localization assay is not 
sufficient. To make a distinctive conclusion, other experiments are required. Additionally, a better 
comparison can be done by performing a co-transfection of YFP-hMLH1 wild type and GFP-
hMLH1-R389W in HCT116 cell line. Confocal laser-scanning microscopy can be used to evaluate 
the similarity of their subcellular localization.  
Moreover, it has been reported that MLH1 can only enter the nucleus by forming 
heterodimer with PMS2 that unmasks NLS of MutLα [Wu, et al., 2003]. If our assumption is 
correct, we can also suggest that hMLH1-R389W may restore the hPMS2 stability and import into 
the nucleus in complex with PMS2.  
Furthermore, the mutation hMLH1-R389W happens at the linker domain (chapter 6). In 
principle, this position of hMLH1 is not responsible for the APTase activity, the protein stability, 
the hPMS2 interaction and the nuclear translocation capability. These characteristics may also be 
correlated to the results of our experiment. 
 On the other hand, YFP-fused hMLH1-R389W is overexpressed in the cells. Hence, it 
might be able to enter the nucleus alone. Moreover, we cannot really know whether the endogenous 
hPMS2 is upregulated to the level of YFP-fused hMLH1-R389W in order to heretodimerize with it. 
To test whether hMLH1-R389W is in fact restoring hPMS2 stability, we can carry out other 
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functional assays. For example, hMLH1-R389W can be transfected into HCT116 cells, and the 
protein extracts from the cells can be analyzed by immunoblot assay. 
However, even if the outcome of our investigation would have shown that the hMLH1-
R389W can enter the nucleus similarly to the hMLH1 wild type, the pathogenicity of the C.1165 
c>t R389W hMLH1 mutation would not be concluded.  The reasons for that are the following: 
1) The mutation causes the amino acid change from arginine (a positively charged basic amino 
acid) to tryptophan (a neutral hydrophobic amino acid with aromatic R group). This is a 
nonconservative change, possibly resulting in the polarity change of the amino acid and 
leading to protein structure change.  
2) Several additional functional assays have to be performed to get a complete understanding 
of its pathogenic nature.  
Yet, there are also two other reasons supporting the pathogenetic nature of the mutation: 
3) The patient with this mutation already fits the Amsterdam criteria II as we have described in 
one of the previous chapters.   
4) A 60 years old American patient with same mutation is also suffering from a colorectal 
cancer [Samowitz, et al., 2001]. 
10. Conclusion 
The evaluation of hMLH1-R389W mutation in patients with suspected HNPCC is carried out 
on the basis of: 1) medical pedigree analysis; 2) nuclear localization assay of the protein in question; 
3) empirical and theoretical support from other literatures. First of all, the medical family history of 
patient that carries C. 1165 c>t R389W hMLH1 mutation fulfils the Amsterdam Criteria II. 
Therefore, the patient is considered to be HNPCC-related from the clinical point of view. 
By performing an experimental analysis of subcellular localization of the hMLH1-R389W 
protein in HCT116 and HCT116+chr.3 cell lines, we suggest that the protein might still be 
proficient in translocating into the cells nucleus.  
Some other relevant studies correlate with our experimental result, and support our suggestion. 
The position of the mutation R389W is in the linker domain of hMLH1. The linker domain is 
normally not responsible for: 1) the ATPase activity of hMLH1; 2) the stability of hMLH1; 3) the 
capability of interacting with hPMS2; 4) the proficiency of nuclear localization of hMLH1. 
On the other hand, other studies remind us that: 1) the hMLH1-R389W mutation is a 
nonconservative mutation, which can affect the protein function by changing its structure; 2) the 
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pathogenic nature of the mutation cannot be concluded from only one functional assay; 3) further 
analysis might be based on the RNA splicing deficiency.  
All in all, the pathogenicity of C. 1165 c>t R389W hMLH1 mutation still remains in question, 
and needs further investigation. 
11. Perspectives 
To make a complete evaluation of the pathogenicity of C.1165 c>t R389W hMLH1 mutation, 
numbers of further investigations have to be conducted. The investigations should be developed on 
the basis of two kinds of approaches, namely clinical approaches as well as biological and 
biochemical approaches.  
Clinically, knowing more about the genetic inheritance in the HNPCC-related family (figure 3) 
would be very helpful for diagnosing other members of this family with HNPCC. For example the 
DNA sequencing of the MMR associated genes for individuals 8 and 12 can be carried out.  In this 
case we would be able to find out whether these patients carry the C. 1165 c>t R389W hMLH1 
mutations and whether the mutation is associated with the hereditary cancer. Additionally, having 
more medical information about other families with the same mutation would also be constructive 
when evaluating the mutation. For example, knowing that other patients with this mutation develop 
cancer within the “HNPCC spectrum” would be strongly suggestive that the nature of the mutation 
is pathogenic. 
Other studies can be pursued based on biological and biochemical approaches. First of all, 
some improvements can be made in our experiment. A successful wild type vector (pEYFP-hMLH1) 
transfection in HCT116 cell line is necessary to provide a comparison with the mutant type 
(pEYFP-hMLH1-R389W) transfection. Unfortunately, the subcellular localization of hPMS2 
cannot be deteced in our experiment. The way we deduce its localization in this project is through 
the empirical and theoretical idea. By designing another investigation this deduction can be 
conformed experimentally. Co-transfection of YFP-hMLH1 and GFP-hPMS2 in HCT116 cell line 
followed by confocal laser-scanning microscopy is designed to monitor the subcellular localization 
of both proteins. Moreover, other cell lines, for example 293T, can be used for transfection. 
Furthermore, a numbers of other functional assays have to be carried out to ensure the 
proficiency of the protein. Functional assays for physical protein-protein interaction (e.g. Yeast 
two-hybrid assay, GST pull-down assay and IVTT, and Co-immunoprecipitation and immunoblot 
assay) are required to test the interaction between the hMLH1 mutant and the hPMS2 wild type. 
Additionally, other protein- protein interactions, for example hMLH1-hPMS1, hMLH1-hMLH3, 
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MutL-MutS, MutL-hEXO, etc can also be examined and evaluated. Functional assay involving 
quantitative testing of the repair efficiency in a cell system is desirable as well. For instance this can 
be done by cell-based in vitro MMR functional assay using a human expression system.  
However, even if all functional assays reflect a phenomenon of normal polymorphisms, we 
cannot exclude the possibility of pathogenicity of this mutation due to the RNA splicing. As all the 
functional assays are cDNA-based assays, the deficiency involving RNA splicing machinery is not 
included in the scope of these assays. The exonic splicing enhancer (ESE), which is discrete motif 
of 6 to 8 nucleotides situated within exons, plays an important role in exon recognition [Gorlov, et 
al., 2003]. Missense mutations in ESE are therefore crucial for the RNA splicing. For example, a 
missense mutation C.1976 g>a is suggested to have an abnormal splicing of exon 17 [Raevaara, 
2005]. In order to deal with this problem, further analysis on mRNA level (e.g. mRNA sequence) 
can be pursued as a next step of the research. 
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Appendix I 
DNA Transfection 
Transfection is a common technique characterized by introduction and subsequent 
integration of foreign genetic material in recipient eukaryotic cells. In non-viral experiment the term 
transfection is usually referred to mammalian cells in order to avoid confusion with the non-viral 
transformation of genetic material into bacterial or non-animal eukaryotic cells (fungi, algae, plant 
cells).  
The uptake of genetic material during the transfection in animal cells happens through the 
transient openings in the cells plasma membrane. The transfected material can be supercoilled DNA, 
siRNA constructs and even large molecules, such as proteins.  
There are several methods commonly used for transfection investigations, depending on the 
experimental set up. Some chemical materials are used as carriers of the genetic material for 
transfections. These chemicals are classified into three main classes: (cationic) polymers, liposomes 
and nanoparticles. Other transfection methods involve nucleofection, electroporation, heat shock 
and magnetofection. Transfection can also be carried out by means of proprietary transfection 
reagents. One of them is Lipofectamin that has been used in our experiment. 
Lipofectamin is commonly used in lipid-based in vitro techniques, known as liposome 
transfection, or more commonly lipofection. Liposomes are some artificially created spherical 
vesicles produced from natural phospholipids and cholesterol. These molecules are extremely 
versatile in composition and application. One of their features is the ability to bind a variety of 
lipophillic derivatives, including the genetic material.  
During lipofection lipofectamine alters the cellular plasma membrane and creates some 
openings. This allows the transient genetic material attached to the surface of the liposomes to 
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merge through the membrane by endocytosis. This passage is tacking place because both liposomes 
and the plasma membrane are made of phospholipid bilayers. After endocytosis the genetic material 
is detached from the liposomes and released into the cells. This process is described on the figure 7 
below: 
 
Figure 7: DNA Transfection [http://www.molecularstation.com/transfection/]. 
The figure shows a general representation of a transfection procedure in an animal cell. A genetic 
material in the form of a plasmid, or a vector DNA is transfected by lipofection in the presence of a 
transfection reagent. Liposome enters the cell by endocytosis and subsequently releases its cargo (the genetic 
material) into the cell. 
After the genetic material is released into the cell, it has to be expressed. This can happen in 
two ways. The foreign genetic material is not necessarily transfected into the nuclear genome. In 
this case the genetic material would be eventually lost as a consequence of cell mitosis. This type of 
DNA incorporation is known as transient transfection. Although this type of transfection is suitable 
for some applications, in many cases a stable transfection is a more desirable method.  
In this type the transfected genetic material is actually expected to remain in the genome of the cell 
and to be passed to later cell generations. This is achieved by carrying out a co-transfection, in 
which the co-transfected gene has a resistance to some kind of toxin. In this case the cells can select 
which gene to insert. Some of the cells would let the foreign co-transfected gene in simply by 
chance. Then when the toxin is introduced only the cells with the co-transfected gene in their 
genome would survive and proliferate, while the other cells would die.   
 
 
Molecular Biology Bachelor Project 
June 2008 52
 
 
 
Appendix II 
Full fluorescent microscopic images 
1. Background light image of pEYFP transfected HCT116 cell line 
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2. UV light image of pEYFP transfected HCT116 cell line 
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3. Background and UV light image of pEYFP transfected HCT116 cell line 
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4. Background light image of pEYFP-hMHL1 transfected HCT116 cell line 
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5. UV light image of pEYFP-hMHL1 transfected HCT116 cell line 
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6. Background and UV light image of pEYFP-hMHL1 transfected HCT116 cell 
line 
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7. Background light image of pEYFP-hMHL1-R389W transfected HCT116 cell 
line 
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8. UV light image of pEYFP-hMHL1-R389W transfected HCT116 cell line 
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9. Background and UV light image of pEYFP-hMHL1-R389W transfected 
HCT116 cell line 
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10. Background light image of pEYFP transfected HCT116+ chr.3 cell line 
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11. UV light image of pEYFP transfected HCT116+ chr.3 cell line 
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12. Background and UV light image of pEYFP transfected HCT116+ chr.3 cell 
line 
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13. Background light image of pEYFP-hMLH1 transfected HCT116+ chr.3 cell 
line 
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14. UV light image of pEYFP-hMLH1 transfected HCT116+ chr.3 cell line 
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15. Background and UV light image of pEYFP-hMLH1 transfected HCT116+ 
chr.3 cell line 
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16. Background light image of pEYFP-hMLH1-R389W transfected HCT116+ 
chr.3 cell line 
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17. UV light image of pEYFP-hMLH1-R389W transfected HCT116+ chr.3 cell 
line 
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18. Background and UV light image of pEYFP-hMLH1-R389W transfected 
HCT116+ chr.3 cell line 
 
 
 
 
 
 
 
 
 
 
 
 
